Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Iron Metabolism in Restless Legs Syndrome
NCT00685815Phase 2Completed
- Sponsor
- American Regent, Inc.
- Start
- Nov 2006
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in restless legs syndrome (RLS) comparing Ferric carboxymaltose with Placebo (2 arms). Primary endpoint: Duration Off Treatment at 52 weeks. Started Nov 2006; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NCT00685815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00685815.